Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to zuranolone in adults with major depressive disorder after inadequate response to prior antidepressant therapy
jRCTs031260340Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of zuranolone in major depressive disorder (MDD), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change in HAM-D17 total score from Visit 2 to Visit 4. Started Aug 2026; status: recruiting.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCTs031260340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260340.